Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tasadenoturev - DNAtrix/University of Texas M. D. Anderson Cancer Center

Next Previous
Drug Profile

Tasadenoturev - DNAtrix/University of Texas M. D. Anderson Cancer Center

Alternative Names: Ad-delta24-RGD; Ad-DNX 2401; Ad5-Delta 24RGD; Ad5-delta24-RGD; Adenovirus DNX 2401; Adenovirus-5 delta 24 RGD; Delta 24 RGD 4C; Delta-24-RGD; Delta-24-RGD-H43m; DNX 2401; IE-CRAd; RGD-delta24; Tasadenoturev

Latest Information Update: 10 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DNAtrix; University of Texas M. D. Anderson Cancer Center
  • Developer Alcyone Therapeutics; Clinica Universidad de Navarra; DNAtrix; Merck & Co; University of Alabama Comprehensive Cancer Center; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I Diffuse intrinsic pontine glioma
  • Preclinical Rhabdoid tumour; Teratoma
  • No development reported Gliosarcoma; Ovarian cancer

Most Recent Events

  • 20 Sep 2023 Pharmacodynamics data from a phase-I trial in Glioblastoma presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
  • 20 Sep 2023 Pharmacodynamics data from a preclinical trial in Glioblastoma presented at the Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)
  • 11 Apr 2023 Phase-I development is ongoing in Diffuse intrinsic pontine glioma(First-line therapy, In adolescents, In children, In infants) in Spain (Intratumoural, Injection) (DNAtrix Pipeline, April 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top